Product Information
BIKTARVY 50-200-25 MG TABLET is a brand product labeled by Gilead Sciences, Inc., priced at $136.7331 per EA under NDC 61958250103. Its NADAC has been published 267 times since Jul 14, 2021.
FDA first approved this application on Feb 7, 2018.
BIKTARVY 50-200-25 MG TABLET
bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarateStrength
50; 200; 25 mg/1; mg/1; mg/1
Manufacturer
Gilead Sciences, Inc.NDC
61958250103
Classification
Brand
Dosage Form
TABLET
Route
ORAL
Effective Date
8/19/2026
Active Ingredients
BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATEApproval Type
New Drug (NDA)
FDA Application
NDA210251FDA Approved
2/7/2018
On Market Since
2/7/2018
Pharmacological Classes
Price Statistics
The NADAC for BIKTARVY 50-200-25 MG TABLET has been published 267 times since Jul 14, 2021, and over the history we have for it it has risen 24.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $136.7331 per EA |
|---|---|
| All-time high | $136.7462 (Aug 12, 2026) |
| All-time low | $109.4936 (Aug 18, 2021) |
| 52-week high | $136.7462 |
| 52-week low | $136.6967 |
| Median price | $128.7920 |
| Average price | $125.6662 |
| Largest weekly change | +5.9% (Jan 15, 2025) |
| Weeks tracked | 267 |
| Tracking since | Jul 14, 2021 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of BIKTARVY 50-200-25 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for BIKTARVY 50-200-25 MG TABLET, manufactured by Gilead Sciences, Inc., is $136.7331 per EA (NDC 61958250103), effective Aug 19, 2026.
How has the price of BIKTARVY 50-200-25 MG TABLET changed over time?
Over the history we have for it, the NADAC for BIKTARVY 50-200-25 MG TABLET has risen 24.8%. It has been tracked across 267 weekly CMS publications since Jul 14, 2021.
What are the highest and lowest recorded NADAC prices for BIKTARVY 50-200-25 MG TABLET?
Since Jul 14, 2021, the NADAC for BIKTARVY 50-200-25 MG TABLET has ranged from a low of $109.4936 (Aug 18, 2021) to a high of $136.7462 (Aug 12, 2026), with a median of $128.7920 per EA.
Are there cheaper alternatives to BIKTARVY 50-200-25 MG TABLET?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as BIKTARVY 50-200-25 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures BIKTARVY 50-200-25 MG TABLET?
BIKTARVY 50-200-25 MG TABLET (NDC 61958250103) is labeled by Gilead Sciences, Inc., and CMS classifies it as a brand product.